MUMO 1
Alternative Names: MUMO-1; MuMO1Latest Information Update: 28 Feb 2025
At a glance
- Originator ESTEVE
- Developer ESTEVE; Purdue Pharma
- Class Analgesics; Small molecules
- Mechanism of Action Sigma-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Pain in Spain
- 10 Feb 2023 MUMO 1 is still in phase-I trials for Pain in Spain (ESTEVE pipeline; February 2023)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Pain in Spain